Company Overview and News
Peninsula Mines Ltd (ASX:PSM) has been granted a key exploration and mining tenement at its Gapyeong Graphite Project 50 kilometre east of Seoul in South Korea.
Peninsula Mines Ltd (ASX:PSM) has commenced a flake-graphite resource drilling program at its Eunha Graphite Project in the Chungnam Province, South Korea.
Peninsula Mines Ltd (ASX:PSM) has received high-purity graphite concentrate results which confirm the potential of the high-grade Gapyeong graphite deposit in South Korea.
Peninsula Mines Ltd (ASX:PSM) has intersected significant zinc and lead sulphides in drilling at the Python target of the Ubeong Zinc Project in South Korea.
Peninsula Mines Ltd. (ASX:PSM) managing director Jon Dugdale speaks to Proactive Investors about the South Korea-focused company's advancements in base metals, as well as developments in its integrated graphite strategy.
Peninsula Mines Ltd (ASX:PSM) managing director has demonstrated his confidence in the company’s integrated South Korean graphite production and processing strategy by acquiring shares on-market.
Peninsula Mines Ltd (ASX:PSM) has identified very high-grade zinc in previous drilling of the Ilweol tenements at its Ubeong Zinc Project in South Korea.
Peninsula Mines Ltd. (ASX:PSM) managing director Jon Dugdale speaks to Proactive Investors about the company’s operations in South Korea spanning base metals, battery metals, and now potentially value-added spherical graphite processing.
Peninsula Mines Ltd (ASX:PSM) has launched a program to test value-added processing of very high-purity spherical graphite for use in lithium-ion batteries.
Peninsula Mines Ltd (ASX:PSM) is focused on positioning itself to capture maximum value within the graphite production and downstream processing chain in south Korea - the world’s largest producer of lithium-ion (graphite) battery technology.
DNI PSM DMNKF
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to ASX:PSM / PENINSULA MINES LIMITED on message board site Silicon Investor.
|Peregrine Semiconductor (PSMI)||PSM Holdings recent acquisitions and aggressive growth strat|
|Pioneer Metals (T.PSM)|